Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 7 | 3 | 7 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 5 | 1 | 2 | 0 | 0 |
2M Ago | 1 | 1 | 5 | 0 | 0 |
3M Ago | 0 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $274.41, a high estimate of $364.00, and a low estimate of $200.00. Surpassing the previous average price target of $272.25, the current average has increased by 0.79%.
Breaking Down Analyst Ratings: A Detailed Examination
An in-depth analysis of recent analyst actions unveils how financial experts perceive Biogen...
Login or create a forever free account to read this news
Sign up/Log in